Digital interactions increasingly shape how we engage with brands, yet the ones that leave the strongest impression often do so by being almost invisible.
The pace of change in drug discovery and clinical development has been unmatched in recent years, with technologies such as AI accelerating these processes.
Every patient, every doctor or nurse, every hospital worker is a human being influenced by their experiences outside of healthcare. In the consumer world, we have all come to expect speed and inter
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
